Why real-world HCP insight is becoming a commercial advantage

Tern plc

Pharma companies have used healthcare professional personas for years, but many are still built on limited interviews, workshops and internal assumptions. That makes them useful for alignment, but less useful for execution. If personas do not reflect how clinicians actually think, speak and make decisions in practice, they can weaken messaging, waste spend and reduce the impact of evidence.

Traditional approaches tend to capture what healthcare professionals say in a formal research setting. They are less effective at showing what drives behaviour in real clinical environments, where time pressure, patient complexity, reimbursement issues and changing guidance all shape decisions. As a result, a persona can look credible on paper while failing to explain what really affects uptake.

If a company is working from an outdated or simplified view of its audience, it may focus on the wrong barriers, use evidence in the wrong way or miss the language that actually builds confidence.

The value here is not simply richer insight. It is better accuracy. Real-world language can reveal how clinicians frame problems, what concerns they return to, what evidence they trust and what practical issues affect action. That produces a more grounded view of the audience and gives teams a stronger basis for message development.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Search